Coverage
Filings
Orion's collaboration partner Bayer announced U.S. FDA approval for darolutamide, an androgen receptor inhibitor (ARi), for metastatic hormone-sensitive prostate cancer (mHSPC).
| 6 May 2024 |
| Orion Corporation: Managers' transactions - Karen Lykke Sørensen | 6 May 2024 |
| Orion Corporation: Managers' transactions - Eija Ronkainen | 6 May 2024 |
| Orion Corporation: Managers' transactions - Hilpi Rautelin | 6 May 2024 |
| Orion Corporation: Managers' transactions - Ari Lehtoranta | 6 May 2024 |
| Composition of the Nomination Committee of Orion Corporation | 26 Apr 2024 |